Online inquiry

IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13990MR)

This product GTTS-WQ13990MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets GP gene. The antibody can be applied in Ebola virus infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_066246.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 911829
UniProt ID Q05320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13990MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14876MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ5240MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ7245MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ6953MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ14442MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ14797MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ6531MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ102MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1121B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW